**Retrospective Analysis of Prognostic Value of Neutrophils to lymphocyte Ratio and Platelet Count in Patients with Colorectal Carcinoma**

Mohamed Elbassiouny, Dina Ragab, Ghada Refaat, Suhad A. Ali

Department of Clinical Oncology and Nuclear Medicine

Faculty of Medicine – Ain Shams University

[suhadmaidan89@gmail.com](mailto:suhadmaidan89@gmail.com)

**Abstract: Background:** Colorectal cancer (CRC) is the third most common cancer in men and second in women with 1.8 million new cases (1,026,000 men and 823, 3 women) and almost 881.000 deaths. Rates are substantially higher in males than in females Worldwide in 2018***.* Aim of the work:** In this retrospective study we aimed to evaluate the prognostic impact of baseline NLR and platelet count on the clinicopathological factors and outcome in patients of all stages Colorectal cancer treated from1st of January 2014 to the end of December 2016 in Department of Clinical Oncology and Nuclear Medicine, Ain Shams University hospitals, Cairo, Egypt. **Patients and methods:** Out of 409 patient's medical records in the GI oncology unit, Ain Shams Clinical Oncology Department were reviewed from the period between 1st of January 2014 to 30 December 2016. Total neutrophils, lymphocytic, and platelets' counts were available for only 169 patients. Study ended in 1st of August 2018 with median period of follow up of 27.5 month, ranging between 1/1/2014 to 1/8/2018. All patients (169) were pathologically proven colorectal adenocarcinoma, with age ranging from 18-75 years old (median age: 55.5 yrs). **Results:** Out of 169 patients enrolled in this study, 124 patients were respectable and underwent curative surgeries, 44 patients tumour was right located and 80 patient's tumour located in the left sided colon. 45 patients were metastatic from the start. Postoperative Platelets≥ 310 in our study was statistically significant regarding OS, PFS and DFS (P values <.001, <.001 and 0.007) respectively. Pre-treatment platelet revealed more frequent thrombocytosis in metastatic group than locally advanced group, yet statistically was not significant (P Value=.066). Postoperative NLR ≥2 was significant regarding OS, PFS and DFS among 169 enrolled patients (P values <.001,.002 and <.001) respectively. In the multivariate analysis, elevated postoperative NLR was proven as both independent prognostic and predictor factor for DFS, PFS and OAS. (sig. =.03,.03, ≤0.001 respectively). And platelet count is both independent prognostic factor and predictor for both PFS, OSwith significance =.04, =.03 respectively). **Conclusion:** Abnormal NLR ratio (≥2) acting as a prognostic and predictor of decrease in DFS, PFS and OS in all patients groups. It also showed that abnormal platelet count (≥310) is prognostic and predictor of significant decrease in PFS and OS. Multidisciplinary management is needed to aware surgeons about importance of adequate lymph node dissection, our study showed a statistically significant decrease in OAS in patients underwent inadequate LNs dissection.

**[**Mohamed Elbassiouny, Dina Ragab, Ghada Refaat, Suhad A. Ali. **Retrospective Analysis of Prognostic Value of Neutrophils to lymphocyte Ratio and Platelet Count in Patients with Colorectal Carcinoma.** *Cancer Biology* 2019;9(3):39-51]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>. 6. doi:[10.7537/marscbj090319.06](http://www.dx.doi.org/10.7537/marscbj090319.06).

**Key words:** Neutrophils, lymphocyte, platelet Count, Colorectal Carcinoma

# 1. Introduction

Colorectal Cancer (CRC) is the third most common cancer worldwide and the fourth after breast, lung and prostate cancers in males, the 3rdin females according to latest Surveillance, Epidemiology, and End Results (SEER) data in United States **(1)*.***

In 2017, about 95.520 new cases diagnosed with colon cancer in the United States and about 39.910 cases with rectal cancer (23.720 males and 16.190 females), and an estimated 27,150 men and 23,110 women died from CRC in 2017**(2)*.***

In Egypt, according to the Egypt National Cancer registry, the incidence rates/100.000 population of individual cancer sites are: in Upper Egypt in2008 were 6.2 and 9.6, respectively; in Middle Egypt incidences were 6.7 and 9.7, respectively; while in Lower Egypt values were 8.0 and 10.7, respectively for both males and females **(3)**.

Aside from age and race, many of the known risk factors for CRC including heredity and family history (30% of colorectal cancer is associated with family history and 5% with inherited syndromes such as Familial Adenomatous Polyposis (FAP), Attenuated FAP, and human non-polyposis colorectal cancer), chronic inflammatory bowel disease, overweight, diabetes, obesity, physical inactivity, smoking, alcohol use, low calcium, fiber and folate diet all are considered personal and behavioral risk factors for colorectal cancer **(4)*.***

Surgery is the main treatment modality in treating potentially curable cases aiming at complete removal of tumor with negative margins and involved lymph nodes (LNs). Adjuvant chemotherapy is standard for patients with stage III disease. Its use in stage II disease is controversial, with ongoing studies seeking to confirm which markers might identify patients who would benefit **(5)**.

According to College of American pathologists (CAP) guidelines, factors that were determined to merit inclusion in Category I prognostic factors include: local extend of tumor according to American Joint Committee on Cancer (AJCC), regional Lymph nodes metastasis, residual tumor following surgery with curative intent and tumor grade (considered a stage independent prognostic variable) **(6)*.***

However, it’s increasingly recognized that variations in outcome in cancer patients are not solely determined by the characteristics of the tumor, but also by the host response factors and systemic inflammatory response. **(7)**

The tumor microenvironment, particularly the inflammatory response) especially neutrophil to lymphocyte ratio and platelet count), proven to play an important role in in cancer development and progression **(8)*.***

Interleukin -6 is known to be multifunctional cytokine that acts on variety of cells, stimulates hepatocytes to induce acute phase proteins including CRP and decrease in serum albumin level **(9**).

It elicits that elevated platelets are also related to mechanism underlying host systemic inflammatory response (SIR). So, SIR can be assessed by examining the changes in the cellular components such as neutrophils, lymphocytes, monocytes, and platelets **(10)**.

Over the last 10 years, many international studies investigated those laboratory markers of SIR as prognostic factors in different cancer populations with the best evidence for their use in surgical patients with CRC **(10-13)**.

In 2014, a systematic review and meta-analysis took place in China, itwas carried out based on the data from 16 studies to evaluate the association between NLR and overall survival (OS) and progression-free survival (PFS) in patients with CRC. Results supported that elevated pretreatment NLR predicted poorer OS (HR: 1.813, 95%CI: 1.499–2.193) and PFS (HR: 2.102, 95% CI: 1.554–2.843) in patients with CRC **(14)**.

# Aim of the Work

To evaluate the prognostic impact of baseline NLR and platelet count on the clinicopathologic factors and outcome in patients of all stages Colorectal cancer treated from January 2014 to December 2016 in Department of Clinical Oncology and Nuclear Medicine, Ain Shams University hospitals, Cairo, Egypt.

# 2. Subjects and Methods

**1. Patients**

This retrospective studywas approved by the ethical committee of Ain Shams University in 8th April 2017. The need to obtain informed consent was waived. A retrospective review of the medical records of CRC patients who were registered in the GI oncology unit, Clinical Oncology department, Ain Shams University hospitals was done for a total of 409 consecutive patients in the period between 1st of January 2014 to 30 December 2016 period. Total neutrophils, lymphocytic, and platelets' counts were available in the records of only 169 patients who were registered in the chemotherapy unit, Clinical Oncology department, Ain Shams University hospitals, through which all the data analysis was done.

***They were divided into two groups:***

**First group:** Early and locally advanced (initially non- metastatic)

**Second group:** metastatic cases (metastatic at the time of diagnosis).

Patients were followed till 1/8/2018.

**2. Inclusion and exclusion criteria**

**Inclusion Criteria were**: patients aged 18 years old or more**;** patients who have pathologically proved colorectal adenocarcinoma; and who have started treatment in our department with documented baseline NLR and platelet count.

**3. Data collection**

The files of all patients were reviewed for the following: Date of diagnosis. Personal, medical and family history of the patient. Neoadjuvant treatment data. Adjuvant treatment data. Date of progression in metastatic patients if happened, sites of metastases and type of 1st line of chemotherapy received. Date of recurrence in curative patients, sites of recurrence and chemotherapy received. All initial laboratory data before starting treatment, including carcinoembryonic antigen levels, albumin, granulocyte, leukocyte, lymphocyte, monocyte, neutrophil, and platelet counts. Pathological reports details.

**4- Data interpretation:**

Results were obtained according to some definitions, progression free survival (PFS) was defined as the time elapsed between disease diagnosis (pathology) and tumor progression or death from any cause, with censoring of patients who were lost follow-up. Overall survival (OS) was defined as the time from the date of diagnosis of cancer (pathology), till the date of death due to any cause, last date of follow up, or lost follow up. Disease-Free Survival (DFS) was defined as the time from diagnosis untilrecurrenceoftumorordeathfromany cause.

TNM disease stage was classified according to the American Joint Committee of Cancer, 7th edition **(15)**.

The system used to grade tumor pathological response to neoadjuvant chemoradiation as recommended by the AJCC cancer staging manual, 8th Edition and the CAP guidelines is that as modified from ***Weiser et al* (16)*.***

The response categorized based on modified RECIST Criteria 1.1**(17)*.***

* Evaluation of the performance status of the patients according to the Eastern Cooperative Oncology Group scoring (ECOG) **(18)**.
* Toxicity assessment during treatment was recorded using Common Toxicity Criteria – NCI version 4.03 (CTC - v4.03) **(19)**.

**5- Statistical analysis methods:**

Recorded data were analyzed using the statistical package for social sciences, version 20.0 (SPSS Inc., Chicago, Illinois, USA). Quantitative data were expressed as mean± standard deviation (SD). Qualitative data were expressed as frequency and percentage.

**The following tests were done:**

* Independent-samples t-test of significance was used when comparing between two means.
* Chi-square (x2) test of significance was used in order to compare proportions between two qualitative parameters.
* Receiver operating characteristic (ROC curve) analysis was used to find out the overall predictively of parameter in and to find out the best cut-off value with detection of sensitivity and specificity at this cut-off value.
* **Kaplan-Meier** Survival Analysis: is a descriptive procedure for examining the distribution of time-to-event variables.
* **Log rank** test to compare time-to-event variables by levels of a factor variable.
* The confidence interval was set to 95% and the margin of error accepted was set to 5%.

**Table (1)**: Diagnostic Performance of Laboratory Data in Discrimination of outcome.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **cut-off** | **sen.** | **Spe.** | **PPV** | **NPV** | **Accuracy** |
| CEA | ≥5 | 49% | 85% | 70% | 54% | 56% |
| Alb | ≥4 | 45% | 60% | 88% | 58% | 61% |
| NLR | ≥2 | 68.2% | 75.4% | 78.4% | 64.5% | 75.5% |
| Platelet count | ≥310 | 56.5% | 90% | 90% | 62% | 58.9% |

Sen.: sensitivity, Spe.: Specificity PPV: positive predictive value, NPV: negative predictive value.

# 3. Results

Among patients enrolled in this study, 119 (70.4%) patients have underwent successful diagnostic colonoscopy, while 35 (20.7%) patients were unable to do complete colonoscopy up to the cecum.

169 patients enrolled in this study, 90 patients where located in the left colon, sigmoid and rectum, while 79 patients where located in the right and transverse colon.

**Table (2)**: Demographic data distribution of the patient's groups.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Demographic data (n=169)** | **All patients** | **Non metastatic (n=124)** | **Metastatic (n=45)** | **x2** | **p-value** |
| **Sex** |  |  |  |  |  |
| Female | 103 (60.9%) | 81 (65.3%) | 22 (48.9%) | 3.746 | 0.053 |
| Male | 66 (39.1%) | 43 (34.7%) | 23 (51.1%) |
| **Age (years)** |  |  |  |  |  |
| <40 years | 51 (30.2%) | 40 (32.3%) | 11 (24.4%) | 0.957 | 0.328 |
| >40 years | 118 (69.8%) | 84 (67.7%) | 34 (75.6%) |
| **Address** |  |  |  |  |  |
| Rural | 22 (13%) | 18 (20.9%) | 4 (16.0%) | 0.296 | 0.586 |
| Urban | 89 (52.7%) | 68 (79.1%) | 21 (84.0%) |
| Not recorded | 58 (34.3%) | 38 (30.6%) | 20 (44.4%) |

**Table (3)**: Type of surgery in not metastatic group from the start.

|  |  |
| --- | --- |
| **Surgery** | **Early and locally**  **advanced (n=124)** |
| **Type of surgery** |  |
| APR | 25 (20.16%) |
| LAR | 27 (21.8%) |
| Rt hemicolectomy | 34 (27.4%) |
| Lt Hemicolectomy | 28 (22.6%) |
| Total colectomy | 10 (8.1%) |

All patients in non-metastatic group received Adjuvant chemotherapy,105 patients (84.7%) received FOLFOX/XELOX as a standard protocol for adjuvant treatment in resectable colorectal cancer patients.

Twenty percent of patients received Xeloda/ 5FU instead of platinum based Chemotherapy as an alternative protocol for adjuvant treatment.

**Table (4)**: Adjuvant treatment per stage.

|  |  |
| --- | --- |
| **Stage** | **Treatment** |
| Stage I (8 patients) | All- Observation after Surgery |
| Stage II (42 patients)  Stage III (64 patient) | 11 pt. (Single agent 5FU/Xeloda),21 pt. (oxaliplatin based regimens)  All- FOLFOX/XELOX |
| Stage IV (45 patient) | All- FOLFOX/XELOX |

**Table (7):** Post-surgical details in non-metastatic group.

|  |  |
| --- | --- |
| **Post-surgical details** | **non-metastatic (n=124)** |
| **Adjuvant Type** |  |
| FOLFOX/Xelox | 105 (84.7%) |
| Xeloda/ 5fu | 12 (9.7%) |
| Not recorded | 7 (5.6%) |
| **Recurrence** |  |
| No | 93 (75.0%) |
| Yes | 31 (25.0%) |

**Table (5)**: Site of recurrence distribution of the initially non-metastatic group.

|  |  |
| --- | --- |
| **Site of recurrence** | **(n=31 recurrence)** |
| **Local ( including pelvic LNs )** | 22 (43.9%) |
| **Lung** | 5(16.1%) |
| **Liver** | 8(25.8%) |
| **1st line** |  |
| Received | 26 (83.9%) |
| Not received | 5 (16.1%) |
| Folfiri | 21 (67.7%) |
| Folfox | 5 (16.1%) |

**Table (6)**: Comparison between initially non-metastatic and metastatic according to laboratory data.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Laboratory Data** | **All patients (n=169)** | **Initially Non-metastatic (n=124)** | **Initially metastatic (n=45)** | **t-test** | **p-value** |
| CEA | 0.02-2375  [84.63±302.49] | 34.41±167.57 | 213.33±486.20 | 8.594 | 0.004\* |
| Alb | 1.6-28  [3.85±2.56] | 4.17±2.27 | 3.17±1.74 | 0.858 | 0.359 |
| NLR | 0.4-9.8  [2.51±1.65] | 2.38±1.46 | 2.90±2.06 | 3.308 | 0.071 |
| Platelet count | 89-776  [305.6±144.49] | 293.25±131.15 | 339.44±173.28 | 3.424 | 0.066 |

*\*p-value <0.05 S*

CEA as tumor marker was statistically significant between initially non- metastatic and metastatic groups.

Allmetastatic patients received first line chemotherapy. Oxaliplatin based regimen (FOLFOX or CAPOX) had been received in 42 (93.4%) of metastatic patients with total progression on first line occurred in twenty six patients (57.8%).

**Table (7)**: Distribution of data for the metastatic group (metastatic from the start).

|  |  |
| --- | --- |
| **1st line of metastatic** | **Metastatic (n=45)** |
| **Sites of metastasis** |  |
| Liver | 25(55.6%) |
| Lung | 17(37.8%) |
| Mesenteric LNs | 6(13.3%) |
| Peritoneal | 4(8.9%) |
| Ovary | 1 (2.2%) |
| Bladder | 1(2.2%) |
| **1st line of metastatic** |  |
| FOLFOX / Capox | 42 (93.4%) |
| single agent 5FU/ capecitabine | 2 (4.4%) |
| single agent Irinotecan | 1 (2.2%) |
| **Progressed disease** | 26(57.8%) |

**Table (8)**: Comparison between initially non- metastatic and initially metastatic according to fate.

|  |  |  |  |
| --- | --- | --- | --- |
| **Fate** | **All patients (n=169)** | **Initially non- metastatic (n=124)** | **Initially metastatic**  **(n=45)** |
| On FU | 68 (40.2%) | 59 (47.6%) | 9 (20.0%) |
| Died | 50 (29.6%) | 21 (16.9%) | 29 (64.4%) |
| Lost FU | 51 (30.2%) | 44 (35.5%) | 7 (15.6%) |
| Total | 169 (100.0%) | 124 (100.0%) | 45 (100.0%) |

At the end of this study, fifty patients (29.6%) died, about forty percent (68 cases) enrolled were on F.U at the end of this study.

**Table (9)**: Overall survival in all patients (n=169).

|  |  |  |  |
| --- | --- | --- | --- |
| **Median** | | | |
| **Estimate** | **Std. Error** | **95% C.I.** | |
| **Lower** | **Upper** |
| 50.64 | 9.79 | 31.43 | 69.85 |

**Table (10)**: Disease free survival in the initially non-metastatic group (n=124)

|  |  |  |  |
| --- | --- | --- | --- |
| **Median** | | | |
| **Estimate** | **Std. Error** | **95% C.I.** | |
| **Lower** | **Upper** |
| 19.800 | 2.046 | 15.79 | 23.81 |

**Table (11)**: Progression free survival in the initially metastatic group (n=45).

|  |  |  |  |
| --- | --- | --- | --- |
| **Median** | | | |
| **Estimate** | **Std. Error** | **95% C.I.** | |
| **Lower** | **Upper** |
| 15.00 | 4.62 | 6.54 | 24.66 |

Inadequate LNs dissection (<12 LN) was statistically significant (P Value=.003) with DFS in locally advanced resected patient group. PVI and grade were statistically significant (P Value=.033), (P Value=.048) with PFS.

**Table (12)**: Overall survival based on death between all data characteristics in all patients is shown.

| **Parameters** | | **Median (m)** | | **95% C.I.** | | **Log Rank (Mantel-Cox)** | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Estimate** | **SE** | **Lower** | **Upper** | ***x2*** | **Sig.** |
| **Pathology report** |  |  |  |  |  |  |  |
| Inadequate | No | 27.00 | 2.54 | 22.02 | 31.98 | 9.245 | 0.002\* |
| Done | 17.55 | 2.41 | 14.32 | 20.78 |
| M | No | 31.44 | 2.38 | 26.78 | 36.10 | 10.230 | <0.001\*\* |
| Done | 19.92 | 1.25 | 17.48 | 22.36 |
| Stage | NA | 27.00 | 6.62 | 14.02 | 39.98 | 2.373 | 0.499 |
| I | 46.80 | 28.03 | 0.00 | 101.73 |
| II | 33.12 | 9.32 | 14.84 | 51.40 |
| III | 30.48 | 3.99 | 22.66 | 38.30 |
| Grade | NA | 11.88 | 1.08 | 9.77 | 13.99 | 6.036 | 0.110 |
| I | 12.24 | 1.02 | 9.28 | 13.29 |
| II | 32.40 | 3.27 | 26.00 | 38.80 |
| III | 15.12 | 2.86 | 9.51 | 20.73 |
| PNI | No | 32.40 | 2.59 | 27.33 | 37.47 | 1.521 | 0.217 |
| Done | 21.60 | 3.57 | 14.61 | 28.59 |
| PVI | No | 32.40 | 3.18 | 26.16 | 38.64 | 5.328 | 0.021\* |
| Done | 15.60 | 3.76 | 8.24 | 22.96 |
| Mucinous activity | No | 27.96 | 3.03 | 22.02 | 33.90 | 1.324 | 0.250 |
| Done | 33.12 | 6.48 | 20.41 | 45.83 |
| Peritoneal disease | No | 31.44 | 3.00 | 25.56 | 37.32 | 0.546 | 0.460 |
| Done | 25.20 | 3.56 | 18.22 | 32.18 |
| Underlying disease | No | 32.40 | 3.78 | 24.98 | 39.82 | 0.000 | 0.998 |
| Done | 28.32 | 2.77 | 22.88 | 33.76 |
| Yes | 28.32 | 2.03 | 24.35 | 32.29 |

*P-value >0.05 NS; \*p-value <0.05 S; \*\*p-value <0.001 HS*

This table shows statistically significant between inadequate LN dissections and metastatic disease with Overall Survival (OS).

**Table (13)**: Disease free survival in relation to laboratory data in 1st group (n=124).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory data** | | **Median (m)** | | **95% C.I.** | | **Log Rank (Mantel-Cox)** | |
| **Estimate** | **SE** | **Lower** | **Upper** | ***x2*** | **Sig.** |
| CEA | Normal | 22.80 | 1.92 | 19.03 | 26.57 | 0.024 | 0.877 |
| Abnormal | 21.96 | 5.00 | 12.17 | 31.75 |
| ALB | Normal | 19.20 | 4.22 | 10.93 | 27.47 | 1.376 | 0.241 |
| Abnormal | 20.28 | 7.07 | 6.43 | 34.13 |
| NLR | Normal | 33.00 | 2.28 | 28.52 | 37.48 | 13.652 | <0.001\*\* |
| Abnormal | 12.00 | 1.64 | 8.78 | 15.22 |
| Platelet count | Normal | 25.92 | 1.68 | 22.63 | 29.21 | 7.192 | 0.007\* |
| Abnormal | 7.80 | 0.94 | 5.95 | 9.65 |

*P-value >0.05 NS; \*p-value <0.05 S; \*\*p-value <0.001 HS*

This table shows statistically significance between NLR and platelet count parameters in disease free survival.

**Table (14)**: Progression free survival based on death between laboratory data characteristics in metastatic group (n= 45).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory data** | | **Median (m)** | | **95% C.I.** | | **Log Rank (Mantel-Cox)** | |
| **Estimate** | **SE** | **Lower** | **Upper** | ***x2*** | **Sig.** |
| CEA | Normal | 37.56 | 1.48 | 28.17 | 46.95 | 7.766 | 0.005\* |
| Abnormal | 9.24 | 1.34 | 6.61 | 11.87 |
| ALB | Normal | 10.08 | 2.64 | 4.90 | 15.26 | 0.620 | 0.431 |
| Abnormal | 25.80 | 4.83 | 19.35 | 32.25 |
| NLR | Normal | 25.80 | 4.39 | 17.19 | 34.41 | 9.413 | 0.002\* |
| Abnormal | 8.88 | 1.78 | 5.38 | 12.38 |
| Platelet count | Normal | 25.80 | 3.49 | 18.96 | 32.64 | 19.017 | <0.001\*\* |
| Abnormal | 8.16 | 1.32 | 5.58 | 10.74 |

*P-value >0.05 NS; \*p-value <0.05 S; \*\*p-value <0.001 HS*

This table shows statistically significance between CEA, NLR and platelet count parameters in progression free survival.

N.B: Albumin as a laboratory data was not sufficiently recorded in medical files, so can't comment on its result.

**Table (15)**: Overall survival relation to laboratory data characteristics in all patients.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory data** | | **Median (m)** | | **95% C.I.** | | **Log Rank (Mantel-Cox)** | |
| **Estimate** | **SE** | **Lower** | **Upper** | ***x2*** | **Sig.** |
| CEA | Normal | 33.24 | 4.99 | 22.39 | 44.09 | 11.752 | <0.001\*\* |
| Abnormal | 24.00 | 3.60 | 15.60 | 34.80 |
| ALB | Normal | 50.64 | 7.60 | 32.92 | 73.43 | 3.221 | 0.073 |
| Abnormal | 46.00 | 8.40 | 26.40 | 61.20 |
| NLR | Normal | 41.00 | 6.15 | 26.65 | 59.45 | 46.186 | <0.001\*\* |
| Abnormal | 23.28 | 3.49 | 19.26 | 27.30 |
| Platelet count | Normal | 50.64 | 7.60 | 32.92 | 73.43 | 68.768 | <0.001\*\* |
| Abnormal | 15.12 | 2.27 | 11.24 | 19.00 |

*P-value >0.05 NS; \*p-value <0.05 S; \*\*p-value <0.001 HS*

This table shows statistically significant CEA, NLR and platelet count parameters in overall survival.

**Table (16)**: Relation between NLR according all pathological parameters of all patients.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameters** | | **NLR** | | | | **Chi-square** | |
| **Normal *(n=73)*** | | **Abnormal *(n=96)*** | |
| **No.** | **%** | **No.** | **%** | **x2** | **p-value** |
| Grade | NA | 0 | 0.0% | 3 | 3.1% | 5.284 | 0.152 |
| I | 1 | 1.4% | 1 | 1.0% |
| II | 55 | 75.3% | 55 | 57.3% |
| III | 2 | 2.7% | 7 | 7.3% |
| PNI | No | 47 | 64.4% | 48 | 50.0% | 3.553 | 0.059 |
| Done | 6 | 8.2% | 16 | 16.7% |
| PVI | No | 51 | 69.9% | 57 | 59.4% | 2.095 | 0.148 |
| Done | 2 | 2.7% | 7 | 7.3% |
| Mucinous activity | No | 39 | 53.4% | 45 | 46.9% | 0.134 | 0.715 |
| Done | 19 | 26.0% | 19 | 19.8% |
| Peritoneal disease | No | 38 | 52.1% | 40 | 41.7% | 0.541 | 0.462 |
| Done | 14 | 19.2% | 20 | 20.8% |
| Underlying disease | No | 32 | 43.8% | 40 | 41.7% | 0.67 | 0.413 |
| Done | 17 | 23.3% | 15 | 15.6% |
| Adjuvant Type | 1.00 | 46 | 63.0% | 47 | 49.0% | 2.639 | 0.62 |
| 2.00 | 6 | 8.2% | 6 | 6.3% |
| 3.00 | 4 | 5.5% | 8 | 8.3% |
| 4.00 | 1 | 1.4% | 1 | 1.0% |
| 5.00 | 1 | 1.4% | 4 | 4.2% |
| Recurrence | No | 43 | 58.9% | 50 | 52.1% | 0.043 | 0.835 |
| Yes | 15 | 20.5% | 16 | 16.7% |

*P-value >0.05 NS; \*p-value <0.05 S*

This table shows non-statistically significant relationship between NLR and all patient's parameters.

**Table (17)**: Relation between platelet count according all parameters of the of the patients

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameters** | | **Platelet count** | | | | **Chi-square test** | |
| **Normal (n=104)** | | **Abnormal (n=65)** | | **x2** | **p-value** |
| **No.** | **%** | **No.** | **%** |
| HCV | No | 100 | 96.2% | 63 | 96.9% | 0.069 | 0.793 |
| Yes | 4 | 3.8% | 2 | 3.1% |
| Renal disease | No | 103 | 99.0% | 64 | 98.5% | 0.114 | 0.736 |
| Yes | 1 | 1.0% | 1 | 1.5% |
| Neoadj. | No | 27 | 26.0% | 10 | 15.4% | 1.989 | 0.158 |
| Done | 20 | 19.2% | 15 | 23.1% |
| Type of surgery | APR | 16 | 15.4% | 9 | 13.8% | 2.596 | 0.627 |
| LAR | 15 | 14.4% | 12 | 18.5% |
| Rt hemicolectomy | 24 | 23.1% | 10 | 15.4% |
| Lt Hemicolectomy | 19 | 18.3% | 9 | 13.8% |
| Total colectomy | 8 | 7.7% | 2 | 3.1% |
| Side | Right colon | 30 | 28.8% | 10 | 15.4% | 2.075 | 0.15 |
| Left colon | 52 | 50.0% | 32 | 49.2% |
| Inadequate | No | 52 | 50.0% | 28 | 43.1% | 1.16 | 0.107 |
| Done | 29 | 27.9% | 12 | 18.5% |
| M | No | 82 | 78.8% | 42 | 64.6% | 4.146 | 0.042\* |
| Lung | 22 | 21.2% | 23 | 35.4% |
| Stage | NA | 6 | 5.8% | 4 | 6.2% | 0.863 | 0.834 |
| I | 5 | 4.8% | 3 | 4.6% |
| II | 30 | 28.8% | 12 | 18.5% |
| III | 41 | 39.4% | 23 | 35.4% |
| Grade | NA | 0 | 0.0% | 3 | 4.6% | 3.715 | 0.053 |
| I | 1 | 1.0% | 1 | 1.5% |
| II | 77 | 74.0% | 33 | 50.8% |
| III | 4 | 3.8% | 5 | 7.7% |
| PNI | No | 64 | 61.5% | 31 | 47.7% | 0.112 | 0.738 |
| Done | 14 | 13.5% | 8 | 12.3% |
| PVI | No | 74 | 71.2% | 34 | 52.3% | 2.167 | 0.141 |
| Done | 4 | 3.8% | 5 | 7.7% |
| Mucinous activity | No | 54 | 51.9% | 30 | 46.2% | 1.049 | 0.306 |
| Done | 28 | 26.9% | 10 | 15.4% |
| Peritoneal disease | No | 54 | 51.9% | 24 | 36.9% | 1.144 | 0.285 |
| Done | 20 | 19.2% | 14 | 21.5% |
| Underlying disease | No | 45 | 43.3% | 27 | 41.5% | 2.458 | 0.117 |
| Done | 25 | 24.0% | 7 | 10.8% |
| Adjuvant Type | 1.00 | 63 | 60.6% | 30 | 46.2% | 2.612 | 0.625 |
| 2.00 | 9 | 8.7% | 3 | 4.6% |
| 3.00 | 7 | 6.7% | 5 | 7.7% |
| 4.00 | 1 | 1.0% | 1 | 1.5% |
| 5.00 | 2 | 1.9% | 3 | 4.6% |
| Recurrence | No | 57 | 54.8% | 36 | 55.4% | 3.889 | 0.069 |
| Yes | 25 | 24.0% | 6 | 9.2% |

This table shows non-statistically significant relationship between platelet and all patient's parameters unless extend of the disease at diagnosis (P-value >.042).

**Table (18)**: Logistic Multi-regression analysis of factors affecting NLR diagnosis.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **NLR** | **B** | **Sig.** | **Exp. (B)** | **Lower** | **Upper** |
| Disease free survival | -0.932 | 0.032\* | 1.073 | 0.504 | 2.006 |
| Progression free survival | -0.297 | 0.038\* | 1.526 | 0.717 | 2.854 |
| Overall survival | -2.235 | <0.001\*\* | 2.408 | 1.132 | 4.503 |
| Sidedness | -0.337 | 0.364 | 0.663 | 0.312 | 1.240 |

Binary Logestic Multi-Regression analysis was done for NLR and of DFS, PFS and OS variables that showed statistically significant. It showed that abnormal NLR have predictors and significance decrease of DFS, PFS and OS.

**Table (19)**: Logistic Multi-regression analysis of factors affecting platelet count diagnosis.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Platelet count** | **B** | **Sig.** | **Exp. (B)** | **Lower** | **Upper** |
| Disease free survival | -0.811 | 0.091 | 0.955 | 0.449 | 1.785 |
| Progression free survival | -0.306 | 0.043\* | 1.358 | 0.638 | 2.540 |
| Overall survival | -1.944 | 0.031\* | 2.023 | 0.951 | 3.782 |
| M | -1.020 | 0.047\* | 1.917 | 0.901 | 3.584 |

# Binary Logestic Multi-Regression analysis was done for platelet count and of PFS, OS and M variables that showed statistically significant. It showed that abnormal platelet count have predictors and significance decrease of PFS and OS.

# 4. Discussion

Colorectal cancer remains a prominent cause of cancer morbidity and mortality, despite progress in its management. It is therefore clinically important to discover and validate prognostic markers for the disease that are practical, reliable, and inexpensive. This would help clinicians modulate their plan of management **(20)*.***

Immune and other cells originating from the peripheral blood and recruited to the tumor environment can shape the tumor behavior both directly and indirectly through production of cytokines. More recently, immune cells have come to the forefront of cancer research with the successful introduction of immune blockade inhibitors, drugs that potentiate anti-cancer immune function by blocking inhibitory receptors expressed in lymphocytes (e.g., CTLA4, PD-1) **(21)*.***

Perturbations in the number of immune cells in peripheral blood may be the result of cytokines produced in the tumor which may in turn affect tumor progression. Lymphocytosis has been associated with positive prognosis in various cancers, therefore, increased numbers of circulating lymphocytes may be a marker of increased cytokine signals from the tumor that would mobilize and attract marrow or tissue lymphocytes to the tumor microenvironment where they could attack tumor cells under the right conditions **(22)**.

Neutrophils, on the other hand, have a more controversial role in cancer. Certain subsets of these pro-inflammatory cells may have a pro-tumorigenic effect by induction of immune suppression **(23)**. Due to this effect, neutrophilia has generally been found to be a negative prognostic factor in several malignancies **(24)**.

Thrombocytosis has been associated with adverse canceroutcomes in several cancer sites. Mechanistically, platelets may promote carcinogenesis in several ways, such as a mechanical protection of tumor cells in transit in the circulation, as well as by enriching the tumor micro-environment for several bioactive pro-tumorigenic molecules transported and released from their granules **(25)*.***

The current study was designed to give a close picture to the role of platelet count and neutrophil lymphocyte ratio in relation to progression free survival (PFS), disease free survival (DFS) and overall survival (OS) in colorectal cancer patients. It aimed also at evaluation of the relation between NLR and platelet count with various clinicopathological factors that are known to affect the clinical outcome, as well as exploring if these values could be an independent prognostic factor.

In our study females were more affected than males, 66 (39.1%) were males and 103 (60.9%) were females.

Urban residents constituted 52.7% of cases, while rural residents constituted 13% of cases; this finding is similar to that reported from developed countries. As rural dwellers have a lower incidence of colorectal than urbanities **(26)*.***

Fifty three patients in our study were heavy smokers (31.4%), 29 (17.2%) patients were hypertensive, 24 (14.2%) were diabetic on treatment. Family history was positive in 18.9% of all patients with increased risk but with no statistical significance, may explained by the deficient recording of data, maybe a larger number of patients needed to be investigated.

TNM Classification of Malignant Tumors (TNM) disease stage was classified according to the American Joint Committee of Cancer, 8th edition. In our study, 124 patients presented with early and locally advanced tumors (stage I, II, III) and 45 patients presented with metastatic disease (stage IV).

At the end of this study, 50 patients (29.6%) died, 21 patients were locally advanced and 29 (64.4%) metastatic patients, which is statistically significant difference according to fate (P Value<.001).

Out of 169 patients enrolled in this study, 124 patients were resectable and underwent curative surgeries (right hemicolectomy, left hemicolectomy, APR and LAR).

Out of 124 patients, in 44 patients tumour was right-side located and 80 patient's tumour located in the left sided colon.

In many studies, primary tumor location is a prognostic factor in CRC. In a meta-analysis of 66 studies including 1,427,846 patients with all stages of disease, left-sided primary tumor location (tumor location at or beyond the splenic flexure) was associated with a significantly reduced risk of death and this was independent of stage, race, and use of adjuvant chemotherapy **(27**).

Inadequate lymph node dissection (less than 12 lymph nodes) was noted in 41 (33.1%) patients in resected patients and it was statistically significant for both DFS and OS.

Overall survival was 27 month for adequately resected patients and 17.5 month among inadequately resected patients with P Value =.002.

Disease free survival was 19 month vs. 14 month in 1st group and 2nd group, respectively with P Value =.003).

This met the western literature that recommended that the larger number of nodes may reflect the quality of the surgery and a more complete resection of the mesenteric pedicle, guidelines from expert groups recommend at least 12 nodes be examined histologically to accurately determine nodal status **(28)**.

Histologic grades in our study ranges between grade I-III, found to be statistically significant with disease free survival (P Value=.048).

Disease free survival was 28, 13 and 7.2 months for patients with grade I, II and III tumors, respectively.

Grade reflects the degree of tumor differentiation, poorly differentiated histology is one of the clinicopathological features used to define "high-risk" stage II disease by ASCO, [NCCN,](https://www.uptodate.com/external-redirect.do?target_url=http%3A%2F%2Fwww.nccn.org%2Fprofessionals%2Fphysician_gls%2Ff_guidelines.asp&token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL%2F3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo%3D&TOPIC_ID=2484) and ESMO **(29)*.***

In our study LVI found to be an adverse prognostic factor statistically significant (P Value=.033) which met the western literature that admit tumor invasion into veins or small nonmuscularized vessels is an important prognostic determinantrepresent independent adverse prognostic factors **(30)*.***

Perineural invasion (PNI), mucinous activity and peritoneal disease are generally associated with an increased risk. PNI in the current study was reported only in 58% of patients, mucinous activity reported in 62% and peritoneal disease was reported in 54% only of cases with P Value equals (.21,.25 and.46, respectively) in relation to overall Survival for all patients. This discrepancy may be explained by the deficient recording of the pathological data of patients that has rendered proper assessment of these variables as prognostic variables.

In metastatic group (45 patients) 25 patients (55.6%) were metastatic to liver; 17 patients (37.8%) were metastatic to lung. Among those patients: 7 patients were metastatic to both lung and liver at time of diagnosis.

During follow up of patients who finished adjuvant treatment, recurrence occurred in 31 patients (25%) of all patient group. The most frequent sites of recurrence was locally by 29% (mostly in rectal cancer) and to liver by 25.8% (mostly colonic origin) of the total sites. These results have met the international studies. In 2007 a meta-analysis done in Japan enrolled 5,230 patients who underwent curative resection for colorectal cancer, recurrence occurred in 906 patient (17%). The liver was the most frequent recurrent site (41.1%), the second site was the lung by (27.5%) **(31)**.

Back to pre-treatment laboratory data values, Receiver operating characteristics (ROC) curve was used to define the best cut off value of those laboratory data.

In this study CEA cut-off was ≥ 5, Platelet was ≥310 and NLR was ≥2.

Although the applicable thresholds of NLR, albumin, CEA and platelet count were observed by the ROC curves, the optimal thresholds of these parameters in our study were consistent with other studies and wasn't consistence to the range of some previous studies.

An example for studies resulted in near same cut-off values was a study conducted in 2017 when Chenet al. enrolled 1383 cases with colorectal cancer, PLR cut-off was 210 and NLR cut-off was 2.70**)32)**. In 2017, Absenger et al. conducted a study on 370 colon patients where optimum cut-off NLR was 2.2**(33)**.

On the other hand, here are some previous reportsthat weren't consistence with our values.

Such an example in a study conducted in 2017 in China, optimum cutoff of NLR was 10.5 **(34)**. Also a study conducted in 2018 by Mercier and his colleagues, 152 metastatic colon cancer patients were included. The optimum cut-off of Plt was ≥ 350 and NLR was ≥5.6**(35)**.

In our study **CEA** cut-off was ≥5, with sensitivity of 49% specificity of 85% positive predictive value of 70%, negative predictive value of 54% with diagnostic accuracy of 56%.

CEA value correlates with poorer prognosis in our study as there is statistical significant difference between CEA values in early stages colorectal cancer and stage IV, with P Value=.004, Also was statistically significant with overall survival of all patients (P Value≤.001) which met many western studies discussing the same issue **(32 & 33,36)*.***

In our study Platelet count cutoff was ≥310, with sensitivity of 56.5% specificity of 90% positive predictive value of 90%, negative predictive value of 62% with diagnostic accuracy of 58.9% (according to ROC curve).

Among 169 enrolled patients in the current study, OS, PFS and DFS were shorter in patients with elevated platelet counts than in patients with normal counts with significance statistically, OAS was 50.6 and 15.1 month for normalized and elevated platelet groups, respectively.

Disease free survival was 25.9m for normalized platelet count limb and 7.8 month for the other limb. PFS was 26 vs. 8 months among both limbs.

P values <.001, <.001 and 0.007 respectively.

Values of pre-treatment platelet revealed more frequent thrombocytosis in metastatic group than locally advanced group, yet statistically was not significant (P Value=.066).

These results met the end point of several studies **(36,37)*.***

However, one study revealed a different conclusion. It included 630 patients and used a cut-off platelet count value of more than 450; the authors did not find a significant association between elevated platelet counts and survival **(38)*.***

In our study the **NLR**cut-off was ≥2, with sensitivity of 68.2% specificity of 75.4% positive predictive value of 78.4%, negative predictive value of 64.5% with diagnostic accuracy of 75.5% according to ROC Curve.

Among 169 enrolled patients, OS, PFS and DFS were shorter in patients with elevated NLR ratio than in patients with normalized ratio with significance statistically.

Disease free survival among the initially non metastatic group was 33 month in normalized NLR limb and 12 month in NLR ≥2 limb with P value <.001. Progression free survival among the initially metastatic group was 25.8 month among normalized NLR limb and 8.8 month among NLR ≥2 limb with P Value.002.

Overall survival for all patients was 41 month for normalized ratio and 23 month for NLR ≥2 limb with P value of <.001, which met end point of many international studies **(10,35)*.***

Neutrophil lymphocytes ratio remained significant in the multivariate analysis including OS, DFS and PFS for total number of patients.

In univariate analysis, the elevated postoperative NLR was associated with worse OS, DFS and PFS.

Platelet remained significant in the multivariate analysis and confirmed as independent prognostic factor to Worse OS, DFS and PFs in colorectal cancer patients.

These data are consistence with those showed in some previous studies, as shown in a study conducted by Wanbin et al. **(34)** where the main finding was that NLR confirmed as independent prognostic factor regardless Age, sex and stage in coloncancer patients. Also in previous study conducted by Absenger et al., showed the same results regarding multivariate analysis of those studied factors **(33)*.***

Those data may provide new ideas and evidence for clinical applications aimed at evaluating prognosis in patients with colorectal cancer. A less expensive and simpler method of bio-prediction may therefore be developed in the near future.

Regarding platelet count that can be influenced by several diseases and drugs (including blood coagulation disorders, blood diseases, splenic disease, and aspirin), those factors should be excluded in the future studies to more rigorously demonstrate the prognostic value of platelet counts.

Our study is of retrospective design, small sample size (especially in metastatic group) and single-center experience with exclusion of approximately two third of the initial number of patients for various reasons including absence of many essential data in medical reports, which could not be representative of all CRC patients in general and might weaken the meaning of our finding, so we can't generalize our results.

But at least it helps to recognize more adverse prognostic and predictive factors for newly diagnosed CRC patients and offering appropriate treatment strategies, optimum surveillance schedule and monitoring. It may open the door for further investigation with larger scale and long term follow-up in the near future.

# Conclusion

1. The association between cancer and inflammation was first recognized on the basis of observations that tumors frequently arise at sites of chronic inflammation so many triggers of chronic inflammation increase the risk of developing cancer.
2. This study is demonstrating a strong association between elevated neutrophil count and poor outcome in patients with cancer in both overall survival and disease free survival.
3. This study demonstrates a great link between thrombocytosis and OAS, PFS and DFS in both locally advanced and metastatic sittings.
4. Median of OAS in locally advanced group is 31.4 month while in metastatic group it's 19.9 month, median of DFS in locally advanced group is 19.8 month and PFS in metastatic group is 15 month, with statistically difference.

# References

1. Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics (2016). Available at: (https://seer.cancer.gov/statfacts/html/colorect.html).
2. Siegel RL, Fedewa SA, Anderson WF, et al. (2017): Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J Natl Cancer Inst, Vol. 109, No. 8.
3. Ibrahim AS, Khaled HM, Mikhail NH et al. (2014): Cancer incidence in Egypt: results of the national population based cancer registry program. Journal of cancer Epidemiology; 2014:437971.
4. Lutgens MW, van Oijen MG, van der Heijden GJ et al. (2013): Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis.; 19: 789-799.
5. Protic, M., Stojadinovic, A., Nissan, A., Wainberg, Z., Steele, S. R., Chen, D. C.,…Bilchik, A. J. (2015). Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial. Journal of the American College of Surgeons, 221(3), 643–651.
6. Compton CC, Lawrence Cooper HS, Stanley R et al. (2000): American joint committee on cancer prognostic factors consensus conference, Arch Patho lab Med 124:7. Walsh et al. (2014)
7. Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A.,… Amir, E. (2014). Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute, 106(6.
8. Ohsugi Y, et al., (2007): Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 30:2001–2006.
9. Ishizuka M, Nagata H and Takagi K, et al. (2013): Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer, population study. BJC 109(2): 401-407.
10. McMillan DC (2013): The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5): 534–540.
11. Chua W, Charles KA, Baracos VE and Clarke SJ (2011): Neutrophil/lymphocyte ratio predicts chemotherapy outcome in patients with advanced colorectal cancer, population study. British Journal of cancer 104(8): 1288-1295.
12. Wilson K, Shapiro J, Tebbu N and Jonker DJ, et al. (2017): Analysis of the CO.17 and CO.20 studies Ann Oncol 27 (suppl\_6): 588P.
13. Li M, Liu X and Zhang X, et al. (2014): Prognostic role of neutrophil to lymphocyte ratio in colorectal cancer, systemic review and meta-analysis International journal of cancer;134(10):2403-2413.
14. Amin M.B., Edge S., Greene F. er al. (2017): AJCC Cancer Staging Manual 8th edition. Available online at: https://cancerstaging.org.
15. Weiser M et al. (2018): The American Joint Committee on Cancer (AJCC) of colorectal cancer. 8th edition, 25 (6): 1454–1455.
16. Isenhauera E A, Therasseb P, Bogaertsc J, et al. (2009): New response evaluation criteria in solid tumours: Revised RECIST guidelines (version 1.1). European Journal of Cancer,4 5: 2 2 8 –247.
17. Oken MM, Creech RH, Tormey DC, et al. (1982): Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655.
18. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. (2010): NIH Publication No.09-5410. Available online at website of the National Cancer Institute http://www.cancer.gov.
19. Danielsen, H. E., Hveem, T. S., et al., (2017); Prognostic markers for colorectal cancer: estimating ploidy and stroma. Annals of Oncology, 29(3), 616–623.
20. Voutsadakis IA (2016): Immune blockade inhibition in breast cancer. Anticancer Res; 36:5607–5622.
21. Shibutani M, Maeda K, Nagahara H, et al. (2017): Prognostic significance of the preoperative lymphocyte-tomonoocyte ratio in patients with colorectal cancer. Oncol Lett, 13, 1000–6.
22. Whiteside TL. (2008): The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27, 5904–12.
23. Younes G, Segev Y, Begal J, et al. (2016): The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC). Eur J Gynecol Reprod Biol, 199, 16–20. [
24. Steele M and Voutsadakis IA. (2017): Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma. World J Gastrointest Oncol, 9, 42–49.
25. Wen, D., Zou, W., Wen, X. et al, (2018): Urban–rural disparity in colorectal cancer incidence and increasing trend in relation to socioeconomic development and urbanization in China. Journal of International Medical Research, 46(10), 4181–4196.
26. Petrelli F, Tomasello G, Borgonovo K, et al. (2016): Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncology, 3(2):211-219.
27. De Campos-Lobato LF, Stocchi L, de Sousa JB, et al. (2013): Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemo radiation: it means more than you think!. Ann Surg Oncol; 20(11):3398-3406.
28. Schmoll HJ, Van Cutsem E, Stein A, et al. (2012): ESMO Consensus Guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making. Ann Oncol.; 23(10):2479.
29. Hogan J, Chang KH, Duff G, et al. (2015): Lymphvascular invasion: acomprehensive appraisal in colon and rectal adenocarcinoma. Dis Colon Rectum; 58(6):547-55.
30. Kobayashi H, Mochizuki H, Sugihara K, et al. (2007): Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery, 141, 67-75.
31. Chen J, Zhai E and Yuan Y, et al. (2017): Systemic immune-inflammation index for predicting prognosis of colorectal cancer World J Gastroenterol, 23(34): 6261-6272.
32. Absenger G, Szkandera J, Pichler M et al. (2013): A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer, 109,395–400.
33. Mercier J, Voutsadakis and L A. et al. (2018): Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer.
34. Wang Y, Deng S, Yang Y et al. (2017): The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: A systematic review and meta-analysis. Biomarkers in Medicine; 11(2):195-210.
35. Rao X, Zhang H, and Xu Z, et al. (2018): Poor prognostic role of the pretreatment platelet counts in colorectal cancer. A meta-analysis. Medicine (2018) 97:23.
36. Nyasavajjala SM, Runau F and Datta S, et al. (2010): Is there a role for pre-operative thrombocytosis in the management of colorectal cancer? Int J Surg, 8, 436–8.

7/7/2019